Recursion Pharmaceuticals Inc (RXRX) — Strategic Asset Allocation Index
Recursion Pharmaceuticals Inc (RXRX) has a Strategic Asset Allocation Index of 19.1% as of June 2023. Strategic assets (PP&E of $89.77 Million plus long-term investments of $-) total $89.77 Million, measured against net assets of $468.96 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See RXRX net asset quality score to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Recursion Pharmaceuticals Inc Strategic Asset Allocation Index (2021–2022)
This chart shows how Recursion Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2021 to 2022. As of June 2023, the index stands at 19.1%, representing strategic assets of $89.77 Million against net assets of $468.96 Million USD. For live market cap and overall valuation, see Recursion Pharmaceuticals Inc (RXRX) total market value.
Annual Strategic Asset Allocation Index for Recursion Pharmaceuticals Inc (2021–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Recursion Pharmaceuticals Inc from 2021 to 2022, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Recursion Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 25.0% | $121.45 Million | $121.45 Million | $- | $485.81 Million | ▲ +13.1 pp |
| 2021 | 11.9% | $64.72 Million | $64.72 Million | $- | $542.94 Million | — |